Feb 11, 2009 by Brian Orelli, PhDThe FDA's Bipolar DecisionRisperdal Consta doesn't live up to the agency's high standards.
Feb 10, 2009 by Brian Orelli, PhDRoses and Candy From the FDA?Some drugmakers expect the FDA to bestow its kiss of approval this month.
Feb 9, 2009 by Brian Orelli, PhDViroPharma Cut in HalfThat's what happens when a phase 3 drug doesn't work.
Feb 6, 2009 by Brian Orelli, PhDIcahn vs. Biogen: Round 2What can the activist investor bring to the table now?
Feb 6, 2009 by Brian Orelli, PhD1,111 Reasons to Love This CompanyRobotic surgical assistants are like Barbie. Accessories cost you.
Feb 5, 2009 by Brian Orelli, PhDGlaxo Cuts Jobs, Guidance -- and the Kitchen SinkWith sales dropping, more cuts were inevitable.
Feb 4, 2009 by Brian Orelli, PhDNot If, but When, for LillyA panel of experts adores Lilly's prasugrel, but where's the FDA love?
Feb 4, 2009 by Brian Orelli, PhDThe Tale of 2 DrugmakersMerck and Schering-Plough are headed in opposite directions.
Feb 3, 2009 by Brian Orelli, PhDInterMune Batting .500Half of the company's phase 3 trials meet their primary endpoint.
Feb 2, 2009 by Brian Orelli, PhDHumana's Humming a Happy Tune2009 sure looks a lot brighter than last year for the health insurance company.
Jan 30, 2009 by Brian Orelli, PhDThe Health Benefits of Obama's IT ObsessionDigital health records are on their way, and Wall Street's poised for profit.
Jan 30, 2009 by Brian Orelli, PhDSequenom Is a Rule BreakerThe molecular diagnostic maker has potential.
Jan 30, 2009 by Brian Orelli, PhDCelgene's Double Take Still Looks GoodFor a high grower, this one is likely to keep on growing.
Jan 30, 2009 by Brian Orelli, PhDIcahn's Next TargetThe activist investor tries to board the Amylin train.
